drugset / Trial / NCT06361979
SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases
Timeline
- Start
- 2024-05
- Primary completion
- 2025-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | Intravenous |